Bibliography
- Carter P , FendlyBM, LewisGD, SliwkowskiMX: Development of Herceptin.Breast Dis.11 , 103–111 (2000).
- Yarden Y , SliwkowskiMX: Untangling the ErbB signalling network.Nat. Rev. Mol. Cell Biol.2 , 127–137 (2001).
- Scaltriti M , RojoF, OcanaA et al.: Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.J. Natl Cancer Inst.99 , 628–638 (2007).
- Slamon DJ , ClarkGM, WongSG, LevinWJ, UllrichA, McGuireWL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science235 , 177–182 (1987).
- Slamon DJ , Leyland-JonesB, ShakS et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N. Engl. J. Med.344 , 783–792 (2001).
- Smith I , ProcterM, GelberRD et al.: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.Lancet369 , 29–36 (2007).
- Sauter G , LeeJ, BartlettJM, SlamonDJ, PressMF: Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations.J. Clin. Oncol.27 , 1323–1333 (2009).
- Romond EH , PerezEA, BryantJ et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.N. Engl. J. Med.353 , 1673–1684 (2005).
- Nahta R , EstevaFJ: Trastuzumab: triumphs and tribulations.Oncogene26 , 3637–3643 (2007).
- Fessler SP , WotkowiczMT, MahantaSK, BamdadC: MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells.Breast Cancer Res. Treat.118 , 113–124 (2009).
- Nagy P , FriedlanderE, TannerM et al.: Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a Herceptin-resistant, MUC4-expressing breast cancer cell line.Cancer Res.65 , 473–482 (2005).
- Pusztai L , EstevaFJ: Continued use of trastuzumab (Herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer.Cancer Invest.24 , 187–191 (2006).
- Fujimoo-Ouchi K , SekiguchiF, YamamotoK et al.: Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy.Cancer Chemother. Pharmacol.66 , 269–276 (2010).
- Clynes RA , TowersTL, PrestaLG, RavetchJV: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets.Nat. Med.6 , 443–446 (2000).
- Whiteside TL : The tumor microenvironment and its role in promoting tumor growth.Oncogene27 , 5904–5912 (2008).
- Gunzer K , ClarisseB, LheureuxS, DelcambreC, JolyF: Contribution of glycosylated recombinant human granulocyte colony-stimulating factor (Lenograstim) use in current cancer treatment: review of clinical data.Expert Opin. Biol. Ther.10 , 615–630(2010).
- Tevaarwerk AJ , KolesarJM: Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.Clin. Ther.31(Pt 2) , 2332–2348 (2009).
- Lewis P hillips GD, Li G, Dugger DL et al.: Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody–cytotoxic drug conjugate. Cancer Res.68 , 9280–9290 (2008).